BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lalani AA, Bossé D, McGregor BA, Choueiri TK. Immunotherapy in the Elderly. Eur Urol Focus 2017;3:403-12. [PMID: 29183736 DOI: 10.1016/j.euf.2017.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Boyle H, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, Oudard S, Payne H, Prentice M, Puts M, Aapro M, Droz J. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. European Journal of Cancer 2019;116:116-36. [DOI: 10.1016/j.ejca.2019.04.031] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
2 Pierantoni F, Basso U, Maruzzo M, Lamberti E, Bimbatti D, Tierno G, Bergo E, Brunello A, Zagonel V. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. J Geriatr Oncol 2021;12:290-7. [PMID: 32972885 DOI: 10.1016/j.jgo.2020.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Parker DC, Patel SG, Cookson MS. Evolving Concepts in the Evaluation and Management of Bladder Cancer in Elderly Men. Curr Geri Rep 2019;8:331-7. [DOI: 10.1007/s13670-019-00301-w] [Reference Citation Analysis]
4 Dupuis HGA, Chebbi A, Surlemont L, Rigal O, Di Fiore F, Pfister C, Nouhaud FX. Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma. Transl Androl Urol 2021;10:2418-26. [PMID: 34295728 DOI: 10.21037/tau-20-1481] [Reference Citation Analysis]
5 Hermansen CK, Donskov F. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. J Geriatr Oncol 2021;12:827-33. [PMID: 33388280 DOI: 10.1016/j.jgo.2020.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Panian J, Lin X, Simantov R, Derweesh I, Choueiri TK, McKay RR. The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. Clin Genitourin Cancer 2020;18:e598-609. [PMID: 32280027 DOI: 10.1016/j.clgc.2020.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Basso U, Paolieri F, Rizzo M, De Giorgi U, Bracarda S, Antonuzzo L, Atzori F, Cartenì G, Procopio G, Fratino L, D’arcangelo M, Fornarini G, Zucali P, Cusmai A, Santoni M, Pipitone S, Carella C, Panni S, Deppieri FM, Zagonel V, Tortora G. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers 2022;14:2293. [DOI: 10.3390/cancers14092293] [Reference Citation Analysis]
8 Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017. JAMA Netw Open 2019;2:e199249. [PMID: 31411714 DOI: 10.1001/jamanetworkopen.2019.9249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
9 Lindner AK, Gruenbacher G, Schachtner G, Thurnher M, Pichler R. Rare, but Severe: Vasculitis and Checkpoint Inhibitors. Eur Urol Focus 2020;6:609-12. [PMID: 31072806 DOI: 10.1016/j.euf.2019.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. J Geriatr Oncol 2021:S1879-4068(21)00164-8. [PMID: 34238726 DOI: 10.1016/j.jgo.2021.07.002] [Reference Citation Analysis]
11 Rizzo A, Mollica V, Santoni M, Ricci AD, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. Eur Urol Focus 2021:S2405-4569(21)00058-4. [PMID: 33714725 DOI: 10.1016/j.euf.2021.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C, Casuscelli J. Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. J Geriatr Oncol 2020;11:1061-6. [PMID: 32565147 DOI: 10.1016/j.jgo.2020.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zarrabi K, Wu S. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. Expert Opin Biol Ther 2018;18:695-705. [PMID: 29782188 DOI: 10.1080/14712598.2018.1478962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Popescu T, Karlsson U, Vinh-Hung V, Trigo L, Thariat J, Vuong T, Baumert BG, Motta M, Zamagni A, Bonet M, Myint AS, Lara PC, Nguyen NP, Arenas M. Challenges Facing Radiation Oncologists in The Management of Older Cancer Patients: Consensus of The International Geriatric Radiotherapy Group. Cancers (Basel) 2019;11:E371. [PMID: 30884827 DOI: 10.3390/cancers11030371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]